SubsidieMeestersThe first non-surgical repair for Pelvic Organ Prolapse
Escala Medical's Apyx aims to provide a minimally invasive solution for early-stage pelvic organ prolapse, enhancing quality of life and preventing condition progression through clinical trials and commercialization.
Projectdetails
Introduction
Pelvic Organ Prolapse (POP) affects nearly 50% of women over 40 years old globally. 89% of the cases seek treatment for symptomatic early-stage prolapse.
Current Challenges
Despite the high prevalence and the progression of POP over time, patients currently cannot be offered a repair solution until the condition worsens enough for surgical intervention. However, the surgical interventions of prolapse have several side effects, including:
- Prolonged recovery
- Pelvic pain
- Relapses of POP
Innovative Solution
Escala Medical has developed a minimally invasive and incision-free repair intervention for early-stage POP repair - Apyx. Apyx is the first medical device for treating early-stage prolapse, regaining quality of life and preventing prolapse deterioration for the vast majority of currently unaddressed POP sufferers.
Project Objectives
The EIC project will:
- Finalize the development of Apyx
- Conduct clinical trials
- Support scale-up and commercialization activities
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 5.067.216 |
Tijdlijn
| Startdatum | 1-10-2023 |
| Einddatum | 30-9-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- ESCALA MEDICAL LTDpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Restoring a normal life and dignity for women and men suffering from severe Stress Urinary IncontinenceDeveloping UroActive™, a smart artificial urinary sphincter that offers a safe, convenient, and effective solution for severe urinary incontinence, minimizing side effects and restoring patient dignity. | EIC Accelerator | € 2.499.999 | 2023 | Details |
WOMED: an innovative intrauterine biodegradable polymer-based drug-delivery platformWomed aims to revolutionize uterine disorder treatments with innovative local therapies, starting with a drug-free device for fertility and developing solutions for fibroids and endometriosis pain. | EIC Accelerator | € 2.493.809 | 2024 | Details |
Revolutionary vascular repair patch to treat aortic dissectionsAortyx's biomimetic bioresorbable adhesive patch aims to treat aortic dissections via endovascular deployment, enhancing natural repair and reducing mortality compared to traditional stents. | EIC Accelerator | € 2.500.000 | 2022 | Details |
APAC – the first targeted therapy for peripheral arterial occlusive disease.Aplagon is developing APAC, a targeted therapy for advanced peripheral arterial occlusive disease, aiming to improve safety and efficacy in clinical studies to address high morbidity and mortality rates. | EIC Accelerator | € 2.099.387 | 2022 | Details |
Innovative, minimally invasive Medical Prostatic Retraction Device for the treatment of Benign Prostatic Hyperplasia (BPH) Patients in the office settings.Butterfly Medical is developing a minimally invasive device for BPH treatment that enhances urine flow without surgery, aiming for post-marketing studies in Europe and pivotal FDA trials in the US. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Restoring a normal life and dignity for women and men suffering from severe Stress Urinary Incontinence
Developing UroActive™, a smart artificial urinary sphincter that offers a safe, convenient, and effective solution for severe urinary incontinence, minimizing side effects and restoring patient dignity.
WOMED: an innovative intrauterine biodegradable polymer-based drug-delivery platform
Womed aims to revolutionize uterine disorder treatments with innovative local therapies, starting with a drug-free device for fertility and developing solutions for fibroids and endometriosis pain.
Revolutionary vascular repair patch to treat aortic dissections
Aortyx's biomimetic bioresorbable adhesive patch aims to treat aortic dissections via endovascular deployment, enhancing natural repair and reducing mortality compared to traditional stents.
APAC – the first targeted therapy for peripheral arterial occlusive disease.
Aplagon is developing APAC, a targeted therapy for advanced peripheral arterial occlusive disease, aiming to improve safety and efficacy in clinical studies to address high morbidity and mortality rates.
Innovative, minimally invasive Medical Prostatic Retraction Device for the treatment of Benign Prostatic Hyperplasia (BPH) Patients in the office settings.
Butterfly Medical is developing a minimally invasive device for BPH treatment that enhances urine flow without surgery, aiming for post-marketing studies in Europe and pivotal FDA trials in the US.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A completely biological and human tissue-engineered mesh produced from Cell-Assembled extracellular Matrix (CAM) in vitro for the treatment of Pelvic Organ Prolapse (POP)This project aims to develop a biological, tissue-engineered mesh using Cell-Assembled extracellular Matrix to treat Pelvic Organ Prolapse, demonstrating its safety and effectiveness in preclinical models. | ERC Proof of... | € 150.000 | 2023 | Details |
PELVIc Floor Evaluation live TRACKing – Real-time prediction of perineal traumaPELVITRACK aims to prevent pelvic floor disorders by developing a real-time monitoring solution for perineal tearing during vaginal deliveries through interdisciplinary research and innovative technologies. | EIC Pathfinder | € 3.209.102 | 2025 | Details |
LAPRIXA: the smallest organ blood pressure measurement device in the worldCorporis Medical ontwikkelt een innovatieve bloeddrukmeter om anastomotische lekkage bij slokdarm- en maagresecties te voorspellen. | Mkb-innovati... | € 20.000 | 2020 | Details |
reGeneRative bone Implant for the treatment of hip dysPlasiaGRIP aims to revolutionize hip dysplasia treatment with personalized, 3D-printed regenerative bone implants, enhancing integration and reducing invasiveness compared to current methods. | ERC Proof of... | € 150.000 | 2022 | Details |
A completely biological and human tissue-engineered sling produced from Cell-Assembled extracellular Matrix (CAM) in vitro for the treatment of Stress Urinary Incontinence (SUI)This project aims to develop and validate soft, biologically-based CAM slings for treating Stress Urinary Incontinence, addressing complications of synthetic slings through in vivo testing in sheep. | ERC Proof of... | € 150.000 | 2025 | Details |
A completely biological and human tissue-engineered mesh produced from Cell-Assembled extracellular Matrix (CAM) in vitro for the treatment of Pelvic Organ Prolapse (POP)
This project aims to develop a biological, tissue-engineered mesh using Cell-Assembled extracellular Matrix to treat Pelvic Organ Prolapse, demonstrating its safety and effectiveness in preclinical models.
PELVIc Floor Evaluation live TRACKing – Real-time prediction of perineal trauma
PELVITRACK aims to prevent pelvic floor disorders by developing a real-time monitoring solution for perineal tearing during vaginal deliveries through interdisciplinary research and innovative technologies.
LAPRIXA: the smallest organ blood pressure measurement device in the world
Corporis Medical ontwikkelt een innovatieve bloeddrukmeter om anastomotische lekkage bij slokdarm- en maagresecties te voorspellen.
reGeneRative bone Implant for the treatment of hip dysPlasia
GRIP aims to revolutionize hip dysplasia treatment with personalized, 3D-printed regenerative bone implants, enhancing integration and reducing invasiveness compared to current methods.
A completely biological and human tissue-engineered sling produced from Cell-Assembled extracellular Matrix (CAM) in vitro for the treatment of Stress Urinary Incontinence (SUI)
This project aims to develop and validate soft, biologically-based CAM slings for treating Stress Urinary Incontinence, addressing complications of synthetic slings through in vivo testing in sheep.